Is Novo Nordisk (CPSE:NOVO B) Still Reasonable After New Semaglutide Data?

What happened: Novo Nordisk shares have seen a sharp reset, and new semaglutide data across obesity, liver disease and cardiovascular risk has raised the question of whether the current valuation is still supported by earnings power. Key numbers: Stock price fell 58.8% over the past 3 years. P/E is 9.3x versus a Pharmaceuticals industry average of 21.7x and a peer group average of 26.2x. Why it matters: The Fair Ratio sits above the current 9.3x level, so the shares screen as undervalued on that framework, suggesting sentiment has not fully closed the gap the earnings-based model points to.

Novo Nordisk shares have seen a sharp reset, and new semaglutide data across obesity, liver disease and cardiovascular risk has raised the question of whether the current valuation is still supported by earnings power.

The Fair Ratio sits above the current 9.3x level, so the shares screen as undervalued on that framework, suggesting sentiment has not fully closed the gap the earnings-based model points to.